IP Library Granted Patent US 8,631,631
Granted Patent B2
US 8,631,631 · App. 12/641,434 · Granted Jan 21, 2014

Packaging solutions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,631,631
App. No.
12/641,434
Granted
Jan 21, 2014
Kind
B2
Abstract

Packaging systems for storing ophthalmic devices such as contact lenses and to methods for packaging such ophthalmic devices with solutions to improve the comfort of the lenses during wear are disclosed. A packaging system includes an ophthalmic device stored in an aqueous packaging solution comprising a brush copolymer comprising (a) monomeric units derived from an ethylenically unsaturated monomer containing one or more boronic acid moieties; and (b) monomeric units derived from an ethylenically unsaturated-containing hydrophilic macromonomer.

Claims (26)

1. A method of preparing a package comprising a storable, sterile ophthalmic device, the method comprising:

(a) immersing an ophthalmic device in an aqueous packaging solution comprising a brush copolymer prepared by reacting a 3-methacrylamidophenylboronic acid with a methacrylated PVP macromer to provide a hydrophilic polymer intermediate; reacting the hydrophilic polymer intermediate with a triethylamine followed by the reactive addition of a methacryloyl chloride; removal of any Triethylamine hydrochloride formed; and isolation of a methacrylated polymeric backbone formed there by; and reacting the methacrylated polymeric backbone with a 3-methacylamidophenyl boronic acid and a DMA to provide a brush copolymer comprising (i) monomeric units derived from an ethylenically unsaturated monomer containing one or more boronic acid moieties; and (ii) monomeric units derived from an ethylenically unsaturated-containing hydrophilic macromonomer, wherein the solution has an osmolality of at least about 200 mOsm/kg and a pH in the range of about 6 to about 9;

(b) packaging the solution and the device in a manner preventing contamination of the device by microorganisms; and

(c) sterilizing the packaged solution and device.

2. The method of claim 1 , wherein the ophthalmic device is a contact lens.

3. The method of claim 1 , wherein the ophthalmic device is a silicone hydrogel contact lens.

4. The method of claim 1 , wherein the brush copolymer has a backbone of the monomeric units derived from an ethylenically unsaturated monomer containing one or more boronic acid moieties; and bristles of the monomeric units derived from an ethylenically unsaturated-containing hydrophilic macromonomer.

5. The method of claim 4 , wherein the backbone further comprises monomeric units derived from an ethylenically unsaturated monomer containing a tertiary-amine moiety; and monomeric units derived from an ethylenically unsaturated monomer containing a hydrophilic moiety capable of rendering the copolymer water-soluble.

6. The method of claim 1 , wherein the ethylenically unsaturated monomer containing one or more boronic acid moieties comprises an ethylenically unsaturated containing aryl boronic acid.

7. The method of claim 1 , wherein the ethylenically unsaturated monomer containing one or more boronic acid moieties is selected from the group consisting of 4-vinylphenylboronic acid, 3-methacrylamidophenylboronic acid, 3-acrylamidophenylboronic acid and mixtures thereof.

8. The method of claim 1 , wherein the hydrophilic macromonomer comprises units derived from a hydrophilic monomer selected from the group consisting of an unsaturated carboxylic acid, vinyl lactam, amide, polymerizable amine, vinyl carbonate, vinyl carbamate, oxazolone monomer and mixtures thereof.

9. The method of claim 1 , wherein the hydrophilic macromonomer is made using atom transfer radical polymerization (ATRP) or reversible addition-fragmentation chain transfer (RAFT) polymerization.

10. The method of claim 1 , wherein the hydrophilic macromonomer has a number average molecular weight of about 500 to about 200,000.

11. The method of claim 1 , wherein the brush copolymer further comprises monomeric units derived from an ethylenically unsaturated monomer containing a tertiary-amine moiety.

12. The method of claim 1 , wherein the brush copolymer further comprises monomeric units derived from an ethylenically unsaturated monomer containing a hydrophilic moiety capable of rendering the copolymer water-soluble.

13. The method of claim 1 , wherein the hydrophilic moiety is derived from a hydrophilic monomer selected from the group consisting of N-vinyl pyrrolidone, N-vinyl-N-methyl acetamide, N,N-dimethyl methacrylamide, N,N-dimethylacrylamide, and mixtures thereof.

14. The method of claim 1 , wherein the brush copolymer comprises about 1 to about 20 mole percent of the boronic acid-containing monomeric units, about 1 to about 20 mole percent of the monomeric units derived from an ethylenically unsaturated hydrophilic macromonomer, about 1 to about 20 mole percent of monomeric units derived from an ethylenically unsaturated monomer containing a tertiary-amine moiety, and about 40 to about 90 mole percent of monomeric units derived from an ethylenically unsaturated monomer containing a hydrophilic moiety capable of rendering the copolymer water-soluble.

15. The method of claim 1 , wherein the solution does not contain an effective disinfecting amount of a disinfecting agent.

16. The method of claim 1 , wherein the solution does not contain a germicide compound.

17. A packaging system for the storage of an ophthalmic device comprising a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising a brush copolymer prepared by reacting a 3-methacrylamidophenylboronic acid with a methacrylated PVP macromer to provide a hydrophilic polymer intermediate; reacting the hydrophilic polymer intermediate with a triethylamine followed by the reactive addition of a methacryloyl chloride; removal of any Triethylamine hydrochloride formed; and isolation of a methacrylated polymeric backbone formed there by; and reacting the methacrylated polymeric backbone with a 3-methacylamidophenyl boronic acid and a DMA to provide a brush copolymer comprising (i) monomeric units derived from an ethylenically unsaturated monomer containing one or more boronic acid moieties; and (ii) monomeric units derived from an ethylenically unsaturated-containing hydrophilic macromonomer, wherein the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

18. The packaging system of claim 17 , wherein the ophthalmic device is a contact lens.

19. The packaging system of claim 17 , wherein the package is heat sterilized subsequent to sealing of the package and the solution does not contain an effective disinfecting amount of a disinfecting agent or a germicide compound.

20. A packaging system for the storage of an ophthalmic device comprising:

(a) an aqueous packaging solution comprising a brush copolymer prepared by reacting a 3-methacrylamidophenylboronic acid with a methacrylated PVP macromer to provide a hydrophilic polymer intermediate; reacting the hydrophilic polymer intermediate with a triethylamine followed by the reactive addition of a methacryloyl chloride; removal of any Triethylamine hydrochloride formed; and isolation of a methacrylated polymeric backbone formed there by; and reacting the methacrylated polymeric backbone with a 3-methacylamidophenyl boronic acid and a DMA to provide a brush copolymer comprising (i) monomeric units derived from an ethylenically unsaturated monomer containing one or more boronic acid moieties; and (ii) monomeric units derived from an ethylenically unsaturated-containing hydrophilic macromonomer, wherein the solution has an osmolality of at east about 200 mOsm/kg and a pH in the range of about 6 to about 9;

(b) at least one ophthalmic device; and

(c) a container for holding the solution and ophthalmic device sufficient to preserve the sterility of the solution and ophthalmic device, wherein the solution does not contain an effective disinfecting amount of a disinfecting agent.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →